Q-omics provides the consensus-scored SUV39H1 profile across patient tissues and cancer cell-line models. SUV39H1 expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, SUV39H1 is differentially expressed in 16, with the highest sampling consensus in KIRC. Additionally, SUV39H1 RNA expression shows 18,685 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight ACC, and KIRC as cancer lineages where SUV39H1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SUV39H1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SUV39H1 survival associations across molecular data types. SUV39H1 RNA expression shows survival associations in the most cancer types (22), followed by mutation status (6) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SUV39H1 RNA expression–survival associations across cancer types. High SUV39H1 expression shows unfavorable associations in ACC, KICH, KIRC, LIHC, BRCA and UVM. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for SUV39H1 RNA expression.
This table summarizes SUV39H1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 16, while mass-spec protein shows differences in 4. The strongest signals are observed in KIRC for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for SUV39H1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SUV39H1 shows higher tumor expression in KIRC, COAD, LUAD, HNSC, KIRP and LIHC. The KIRC box plot shows higher SUV39H1 RNA expression in tumor versus normal tissue (log2 FC = +0.816, t-test p < 0.001).
This table shows molecular features associated with SUV39H1 in patient tissues and cancer cell lines. In patient samples, SUV39H1 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, SUV39H1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BREAST, while CRISPR and shRNA rows add functional-dependency signals in UPPER_AERODIGESTIVE_TRACT and BLOOD_Lymphoma.
